Popular Trials
Proteasome Inhibitor
Chemotherapy + Stem Cell Transplant for Multiple Myeloma
Recruiting1 awardPhase 1
Duarte, California
This trial is studying the side effects and best dose of bortezomib when given together with fludarabine phosphate and melphalan with or without total marrow irradiation for patients with high-risk stage I or II multiple myeloma.
Proteasome Inhibitor
Velcade +1 More for Mesothelioma
Recruiting3 awardsPhase 2
New York, New York
Study chemotherapy will consist of four treatments with Velcade (days 1, 4, 15, and 18) and two treatments with Eloxatin(days 4 and 18). Patients will be undergo standard of care blood work and Quality of Life (QOL) questionnaires at each visit and will be have repeat CT scans performed to assess tumor response every 2 cycles (8 weeks). Each patient will be allowed to receive a maximum of 6 cycles of therapy. Following discontinuation of treatment due to disease progression or completion of therapy, patient's will be followed for survival, QOL assessments, and tumor assessments every 3 months (or as clinically indicated) for the first year and every 3 months thereafter for a maximum of 5 years.
Alkylating agents
Chemotherapy Regimen for Multiple Myeloma
Recruiting1 awardPhase 2
Little Rock, Arkansas
This trial is testing a new chemotherapy regimen for myeloma patients who have already had treatment. Results from past studies conducted at MIRT show that patients treated with this new regimen have longer remissions and better responses to treatment than patients who received standard chemotherapy.
Proteasome Inhibitor
Bortezomib + Sorafenib + Decitabine for Acute Myeloid Leukemia
Recruiting1 awardPhase 1
Columbus, Ohio
This trial is testing bortezomib and sorafenib tosylate given with decitabine to see what effects (good and bad) it has on patients with acute myeloid leukemia, and to find the best dose of the drugs to use.
Popular Filters
Phase 3 Trials
Immunomodulatory Agent
Triple Drug Therapy for Multiple Myeloma
Recruiting2 awardsPhase 3
Birmingham, Alabama
This trial is testing a new combination of drugs to treat cancer. The drugs are lenalidomide, bortezomib, and dexamethasone. They are testing it in patients with multiple myeloma who have not been treated before.
Chemotherapy
TT3-LITE Regimen for Multiple Myeloma
Recruiting4 awardsPhase 3
Little Rock, Arkansas
This trial is testing a cancer treatment called S-TT3, which uses high-dose chemotherapy to kill cancer cells. It targets patients needing strong chemotherapy and transplants. The goal is to reduce severe side effects while maintaining treatment effectiveness.
Corticosteroid
Combination Chemotherapy for Multiple Myeloma
Recruiting2 awardsPhase 3
Little Rock, Arkansas
This trial is continuing the research from Total Therapy I and II to explore why chromosome abnormalities found in persons with multiple myeloma affect the outcome of drug therapy used in this disease.
Antimetabolite
Combination Chemotherapy +/− Bortezomib for Lymphoma
Recruiting2 awardsPhase 3
Birmingham, Alabama
This trial is comparing how well two different combination chemotherapies work in treating patients with newly diagnosed T-cell acute lymphoblastic leukemia or stage II-IV T-cell lymphoblastic lymphoma.
Trials With No Placebo
Proteasome Inhibitor
BLd Combination Therapy for Multiple Myeloma
Recruiting1 awardPhase 1 & 2
Boston, Massachusetts
This trial is testing a new combination therapy for multiple myeloma. The goal is to find the highest dose of the combination that can be given safely, and to see how well it works in newly diagnosed patients.
Proteasome Inhibitor
Bortezomib +1 More for Kidney Cancer
Recruiting3 awardsPhase 1 & 2
Los Angeles, California
This research study is for subjects with cancer of the kidney (also known as renal cell carcinoma) that cannot be treated with surgery. The purpose of this study is to see if the combination of bevacizumab and bortezomib is safe and tolerable and can help people with kidney cancer. The investigators would also like to find out what dose of the study drugs can be used safely and effectively, whether the combination of these two drugs can decrease cancer symptoms and stop tumor growth, and how frequently serious side effects might occur with this combination. The study will be conducted in two phases-Phase 1 and Phase 2. In Phase 1, subjects will be assigned to a fixed dose of bevacizumab and different strengths of bortezomib given at 2 different schedules. Phase 2 will depend on how subjects tolerate the doses and schedules of bortezomib in Phase 1. Bortezomib is a type of drug known as a "proteasome inhibitor." By blocking the "proteasome" in cancer cells, bortezomib affects the way these cells divide. Bevacizumab is an inhibitor (blocker) of blood vessel formation. Tumors need blood vessels in order to continue to grow and bevacizumab is thought to work by preventing new blood vessels from growing. Bortezomib (also called Velcade or PS-341) has been approved by the US Food and Drug Administration (FDA) for the treatment of myeloma, but has not been approved for the treatment of kidney cancer. Bevacizumab (also called Avastin) has been approved by the FDA for the treatment of colon cancer, but has not been approved for the treatment of kidney cancer. However, the FDA is permitting the combined use of bortezomib and bevacizumab in this research study. The bevacizumab that will be given in this study is not a commercially marketed product. Although it is expected to be very similar in safety and activity to the commercially available drug, it is possible that some differences may exist. Because this is not a commercially marketed drug, bevacizumab can only be administered to subjects enrolled in this study and may only be administered under the direction of physicians who are investigators in this study. Approximately 40-52 subjects will take part in this study.
Virus Therapy
Virotherapy for Castleman Disease
Recruiting1 awardPhase 2
Bethesda, Maryland
This trial is studying a rare disorder caused by the Kaposi's sarcoma herpes virus (KSHV), which also causes several types of cancer. Researchers want to understand the biology of KSHV-associated multicentric Castleman's disease (MCD) to find ways to treat it.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.